^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TRPV6 overexpression

    i
    Other names: TRPV6, Transient Receptor Potential Cation Channel Subfamily V Member 6, Epithelial Calcium Channel 2, ECAC2, CaT1, Calcium Transport Protein 1, Transient Receptor Potential Cation Channel, Subfamily V, Member 6, Epithelial Apical Membrane Calcium Transporter/Channel CaT1, Alu-Binding Protein With Zinc Finger Domain, Calcium Transporter-Like Protein, HSA277909, CaT-Like, ABP/ZF, HRPTTN, LP6728, TrpV6, CaT-L, ECaC2, CAT1, CATL, ZFAB
    Entrez ID:
    55503
    Related biomarkers:
    Expression
    8ms
    Advances in TRPV6 inhibitors for tumors by targeted therapies: Macromolecular proteins, synthetic small molecule compounds, and natural compounds. (PubMed, Eur J Med Chem)
    However, the development of TRPV6 inhibitors is still in the early stage, and the existing TRPV6 inhibitors have poor selectivity and off-target effects. In this review, we focus on summarizing and describing the structure characters, and mechanisms of existing TRPV6 inhibitors to provide new ideas and directions for the development of novel TRPV6 inhibitors.
    Review • Journal
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    TRPV6 overexpression
    12ms
    TRPV6 Channel Is Involved in Pancreatic Ductal Adenocarcinoma Aggressiveness and Resistance to Chemotherapeutics. (PubMed, Cancers (Basel))
    The knockdown simultaneously led to an increase in apoptotic rates and increased the susceptibility of cells to 5-FU and gemcitabine treatments...Intriguingly, both TRPV6 knockdown and overexpression diminished the process of tumor formation in vivo. This intricate interplay suggests that PDAC aggressiveness relies on a fine-tuned TRPV6 expression, raising its profile as a putative therapeutic target.
    Journal
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    TRPV6 overexpression
    |
    gemcitabine • 5-fluorouracil
    over1year
    Characterization of the TRPV6 calcium channel-specific phenotype by RNA-seq in castration-resistant human prostate cancer cells. (PubMed, Front Genet)
    RNA-seq analysis demonstrated that the calcium channel TRPV6, being a crucial player of calcium signaling, significantly impacts the expression of genes involved in cancer progression, such as cell cycle regulation, chemotaxis, migration, invasion, apoptosis, ferroptosis as well as drug resistance, and extracellular matrix (ECM) re-organization. Our data suggest that the trpv6 gene is involved in and regulates multiple pathways related to tumor progression and drug resistance in castration-resistant prostate cancer cells.
    Journal
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    TRPV6 overexpression
    over1year
    A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Completed, M.D. Anderson Cancer Center | Recruiting --> Completed | N=36 --> 11
    Trial completion • Enrollment change • Metastases
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    TRPV6 overexpression
    |
    SOR C13